BEGIN:VCALENDAR PRODID:-//Microsoft Corporation//Outlook 16.0 MIMEDIR//EN VERSION:2.0 METHOD:REQUEST X-MS-OLK-FORCEINSPECTOROPEN:TRUE BEGIN:VTIMEZONE TZID:Romance Standard Time BEGIN:STANDARD DTSTART:16011028T030000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 END:STANDARD BEGIN:DAYLIGHT DTSTART:16010325T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT ATTENDEE;CN=jgarcia@sistemas-integrados.com;RSVP=TRUE:mailto:jgarcia@sistem as-integrados.com CLASS:PUBLIC CREATED:20190829T151514Z DESCRIPTION:Webinar on Unlocking the potential of patient-centric continuou s innovation: case studies for value added medicines \n \nFeatured speaker :\nSilvia de Alessandris\, PhD\, IQVIA \nValue Added Medicines provide a ran ge of different and important benefits to patients\, healthcare profession als and healthcare systems. Many stakeholders believe innovation only lead s to generating new molecules\, while innovation can come from other areas as well. There is significant untapped potential in Europe to optimise ex isting therapies to best meet the needs of patients\, healthcare professio nals and payers and address remaining healthcare inefficiencies. Enhanced customisation of existing therapies to address existing patient or healthc are needs can lead to better outcomes for the entire healthcare community. \nThe objective of this webinar is to present the findings of the IQVIA pu blication ‘Unlocking the potential of patient-centric continuous innovat ion – case studies for value added medicines’ \nThis study aims to understand key gaps and opp ortunities in the current European HTA/market access processes using value added medicines case studies. Six European countries were assessed to pro vide a representative sample of different European country payer archetype s. The case studies selected are examples of some of the types of patient- centric innovation that value added medicines can bring and also represent each value added medicines category (repositioning\, reformulation and co mbination). \nWith the objective to incentivise continuous optimisation of existing molecules\, calls to action were also proposed to urge adjustmen ts to how decision-makers & healthcare community stakeholders recognise va lue added medicines in the healthcare systems. \nWe welcome your support i n sharing the details of the webinar with your contacts! Thank you!\n \nFo r more information\, please contact cpereira@medicinesforeurope.com \nPlease find the webex details below. \n \n-- Do not delete or change any of the following text. -- \n \nWh en it's time\, join your Webex meeting here. \n \n \nMeeting number (ac cess code): 957 894 665 \nMeeting password: jpJn8wba \n \n \nJoin \n \n \nJoin by phone \nTap to call in from a mobile device (attendees only) \n+32 2894 8317 Belgium Toll \nGlobal call-in numbers \n \nJoin from a video system or applicat ion\nDial 957894665@medicinesforeurope.webex.com \nYou can also dial 62.109.219.4 and enter your meet ing number. \n \nJoin using Microsoft Lync or Microsoft Skype for Busin ess \nDial 957894665.medicinesforeurope@lync.webex.com \n \n \nNeed help? Go to http://help.w ebex.com \n \n \n \n \n \n\n\n\nDisclaimer\n\n The information contained in this communication from the sender is confide ntial. It is intended solely for use by the recipient and others authorize d to receive it. If you are not the recipient\, you are hereby notified th at any disclosure\, copying\, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawf ul.\n\nThis email has been scanned for viruses and malware\, and may have been automatically archived by Mimecast Ltd\, an innovator in Software as a Service (SaaS) for business. Providing a safer and more useful place for your human generated data. Specializing in\; Security\, archiving and com pliance. To find out more Click Here . \n\n DTEND;TZID="Romance Standard Time":20190911T180000 DTSTAMP:20190829T150319Z DTSTART;TZID="Romance Standard Time":20190911T170000 LAST-MODIFIED:20190829T151514Z LOCATION:Videoconference/Teleconference ORGANIZER;CN="Catarina Lopes Pereira - Medicines for Europe":mailto:cpereir a@medicinesforeurope.com PRIORITY:1 SEQUENCE:23 SUMMARY;LANGUAGE=es:[SAVE THE DATE] WEBINAR: Unlocking the potential of pat ient-centric continuous innovation - value added medicines' case studies TRANSP:OPAQUE UID:040000008200E00074C5B7101A82E00800000000303F1FB3992AD501000000000000000 010000000EBA0A3F96247FE4EAD0E3FEC95BC2C95 X-ALT-DESC;FMTTYPE=text/html:\n\n\n\n\n\n\n
Webinar on Unlocking the potential of patien t-centric continuous innovation: case studies for value added medicines
\n
 \;
\n
Featured speaker:
\nSilvia de Alessandris\, PhD\, IQVIA \n
V alue Added Medicines\nprovide a range of different and important benefits to patients \, healthcare professionals and healthcare systems. Many stakeholders beli eve innovation only leads to generating new molecules\, while innovation c an\ncome from other areas as well. There is significant untapped potential in Europe to optimise existing therapies to best meet the needs of patien ts\, healthcare professionals and payers and address remaining healthcare inefficiencies. Enhanced customisation of\nexisting therapies to address e xisting patient or healthcare needs can lead to better outcomes for the en tire healthcare community.
\n
The objective of this webinar is to present the findin gs of the IQVIA publication ‘\;Unlocking the potential of patient- centric continuous innovation –\;\ncase studies for value added medic ines’\;
\n
This\nstudy aims to under stand key gaps and opportunities in the current European HTA/marke t access processes using value added medicines case studies. Six Eur opean countries were assessed to provide a representative sample\n of different European country payer archetypes. The case studies selected are examples of some of th e types of patient-centric innovation that value added medicines c an bring and also\nrepresent each value added medicines category (repositioning\, reformulation and combination).
\n
With the objective to incentivise continuous optimisatio n of existing molecules\, calls to action were also proposed to urge\nadjustments to how decision-makers &\; healthcare community stake holders recognise value added medicines in the healthcare systems.
\n
We welcome your support in sharing the details of the web inar with your contacts! Thank you!
\n
 \;
\n
For more information\, please contact cpereira@medicinesforeurope.com< /u>
\n
Please find the webex details below.
\n\n< col width="40" style="width:24pt\;">\n\n\n\n\n\n\n\n\n\ n\n\n\n\n\n\n\n\n\n\n\n\n
 \;
-- Do no t delete or change any of the following text. --
 \;
\n\n\n\n\n\n\n\n\n
When it's time\, join your Webe x meeting here.
 \;
\n
 \;
\n\n
Meeting number (access code): 957 894 665
Meeting password: jpJn8wba \;
 \;
\n
 \;< /font>
\n\n \n\n\n\n\n\n\n
\n\n\n\n\n\n
Join
\n
 \;
\n
 \;
\nJoin by pho ne \;\n
\n\n
Tap to call in from a mobile device (attend ees only) \;\n
\n\n
+32 289 4 8317 \;Belgium Toll \;\n
\n\n
Global call-in numbers \;\n
\n\n
 \;
\n\n
Join from a video system or application
\n\n
Dial< font size="2">
957894665@medicinesforeurope.webex.com
 \;\n< br>\n\nYou can also dial 62.109.219.4 and enter your meeting number.  \;\n
\n \n
 \;
\n\n\n\n\n\n\n\n\n
Join using Microsoft Lync or Microsoft Skype for Business
Dial 957894665.medicinesforeurope@lync.web ex.com
\n
 \;\n\n\n\n\n\n\n\n \n\n\n\n\n
& nbsp\;
\n\n\n
 \;
Need help? Go to http://help.webex.com
 \;
\n
 \;
\n< div> \;
\n
 \;
\n
\n\ n\n

Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient\, you a re hereby notified that any disclosure\, copying\, distribution or taking action in relation of the contents of this information is strictly prohibi ted and may be unlawful.

This email has been scanned for viruse s and malware\, and may have been automatically archived by Mimecast Lt d\, an innovator in Software as a Service (SaaS) for business. Provid ing a safer and more useful place for your human generated d ata. Specializing in\; Security\, archiving and compliance. To find out m ore Click Here .

\n X-MICROSOFT-CDO-BUSYSTATUS:TENTATIVE X-MICROSOFT-CDO-IMPORTANCE:2 X-MICROSOFT-CDO-INTENDEDSTATUS:BUSY X-MICROSOFT-DISALLOW-COUNTER:FALSE X-MS-OLK-AUTOSTARTCHECK:FALSE X-MS-OLK-CONFTYPE:0 END:VEVENT END:VCALENDAR